# Mentoring Translational Cancer Research in Oklahoma

> **NIH NIH P30** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2024 · $1,072,500

## Abstract

Abstract
Oklahoma faces a significant burden of cancer, with a high incidence and mortality rate. The impact of cancer is
particularly profound among diverse communities, including Native American populations, making it a pressing
concern for our state. Cancer poses a substantial challenge to the health and well-being of our residents, placing
considerable social and economic strain on Oklahoma. The primary objective of this COBRE is to advance
cancer research in Oklahoma. During Phase I and Phase II, our COBRE demonstrated remarkable progress.
Supported Research Project Leaders secured competitive grants, including NIH R01 awards, Department of
Defense grants, and esteemed foundation grants such as the American Cancer Society. Of the total of 375
papers that were published with acknowledgment to our COBRE, COBRE Research Project Leaders and Pilot
Project Leaders authored 246 papers, all of them benefiting from COBRE and COBRE-funded Core support.
The COBRE-supported Cores played a vital role in supporting multiple Investigators, facilitating publications,
and aiding in acquiring federal grants, enriching cancer research in Oklahoma. Phase III seeks to build on this
success, emphasizing sustainability and growth. For Phase III of the COBRE program, our vision is to build upon
our prior achievements, fostering sustainability and growth. We remain dedicated to mentoring and supporting
graduated Research Project Leaders. Our goal is to enhance Core facilities to accommodate evolving cancer
research needs, transitioning them into institutional cancer research Cores. Committed to fostering cross-
disciplinary collaboration and translational research, Phase III COBRE will innovate through the Pilot Grants
Program. These concerted efforts are poised to further advance cancer research in our region, moving us closer
to the coveted designation of a Comprehensive Cancer Center status for our NCI-designated cancer center. The
establishment of such a center will revolutionize cancer prevention and treatment, benefiting our community and
beyond. This Phase III COBRE marks a significant stride toward realizing our vision of a future free from the
burden of cancer, where advanced research and improved clinical practices lead to better outcomes for all.

## Key facts

- **NIH application ID:** 10936135
- **Project number:** 1P30GM154635-01
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** Danny N. Dhanasekaran
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,072,500
- **Award type:** 1
- **Project period:** 2024-08-10 → 2029-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10936135

## Citation

> US National Institutes of Health, RePORTER application 10936135, Mentoring Translational Cancer Research in Oklahoma (1P30GM154635-01). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10936135. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*